Treatment approaches to the low-grade lymphomas

Blood

Volumn 83, Issue 4, 1994, Pages 881-884

  Horning, Sandra J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CONSERVATIVE TREATMENT; DRUG EFFICACY; LYMPHOMA; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; TREATMENT PLANNING;

EID: 0028082459     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v83.4.881.881     Document Type: Review

References (50)

1. Hoppe RT, Kushlan P, Kaplan HS, Rosenberg SA, Brown BW: The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: A preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 58:592, 1981
2. Lister TA, Cullen MH, Beard ME, Brearley RL, Whitehouse JM, Wrigley PF, Stansfeld AG, Sutcliffe SB, Malpas JS, Crowther D: Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. Br Med J 1:533, 1978
3. Portlock CS: Management of the low-grade non-Hodgkin's lymphomas. Semin Oncol 17:51, 1990
4. Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP, Fisher RI: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644, 1993
5. Steward WP, Crowther D, McWilliam LJ, Jones JM, Deakin DP, Todd ID, Blackledge G, Wagstaff J, Scarffe JH, Harris M: Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 61:441, 1988
6. Ezdinli EZ, Harrington DP, Kucuk O, Silverstein MW, Anderson J, O'Connell MJ: The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma. Cancer 60:156, 1987
7. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311: 1471, 1984
8. Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VJ: The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment. Semin Hematol 25:11, 1988
9. Horning SJ, Merigan TC, Krown SE, Gutterman JU, Louie A, Gallagher J, McCravey J, Abramson J, Cabanillas F, Oettgen H: Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial. Cancer 56: 1305, 1985
10. Foon KA, Sherwin SA, Abrams PG, Longo DL, Fer MF, Stevenson HC, Ochs JJ, Bottino GC, Schoenberger CS, Zeffren J: Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 311:1148, 1984
11. O'Connell MJ, Colgan JP, Oken MM, Ritts RJ, Kay NE, Itri LM: Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 4:128, 1986
12. Balkwill FR, Moodie EM: Positive interactions between human interferon and cyclophosphamide or Adriamycin in a human tumor model system. Cancer Res 44:904, 1984
13. Smalley RV, Andersen JW, Hawkins MJ, O'Connell MJ, Oken MM, Borden EC: Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 327:1336, 1992
14. Price CGA, Rohatiner AZS, Steward W, Deakin D, Bailey N, Norton A, Blackledge G, Crowther D, Lister TA: Interferon-alpha 2b in the treatment of follicular lymphoma: Preliminary results of a trial in progress. Ann Oncol 2:141, 1991
15. Hagenbeek A, Carde P, Somers R, Thomas J, de Bock R, Raemaekers J, van Hoof A, van Glabbeke M, Meerwaldt JH: Maintenance remission with human recombinant alpha-2 interferon (Roferon-A) in patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. Results from a prospective randomized phase III clinical trial in 331 patients. Blood 80:74a, 1992 (abstr, suppl 1)
16. Peterson BA, Petroni G, Oken MM, Ozer H: Cylophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas: A preliminary report of an intergroup trial (CALGB 8691 and EST 7486). Proc Am Soc Clin Oncol 12:1240, 1993
17. Solal-Celigny P, Lepage E, Brousse N, Haioun C, Delannoy A, Harousseau JL, Gabarre J, Tilly H, Sebban C, Reyes F, Gisselbrecht C, Coiffer B, for the Groupe d'Etude des Lymphomes de l'Adulte: A concominant treatment with interferon alfa and a doxorubicin-containing regimen improves survival in high-tumor burden follicular non-Hodgkin's lymphomas. 5th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 9-12, 1993, p 54 (abstr)
18. Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, Marmount F, Petrucci MT, Tribalto M, Vegna ML: Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322:1430, 1990
19. Cooper MR: Melphalan/prednisone with and without alfa 2b interferon (IFN) in newly diagnosed multiple myeloma. 15th International Cancer Congress, Hamburg, Germany, August 16-22, 1990, p 986 (abstr)
20. Österborg A, Björkholm M, Björeman M, Brenning G, Carlson K, Celsing F, Gahrton G, Grimfors G, Gyllenhammar H, Hast R, Johansson B, Julivsson G, Järnmark M, Kimby E, Lerner R, Linder O, Merk K, Nilsson B, Ohrling M, Paul C, Simonsson B, Smedmyr B, Svedmyr E, Stalfelt A-M, Strander H, Udén A-M, Ösby E, Mellstedt H: Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: A randomized study from the Myeloma Group of Central Sweden. Blood 81:1428, 1993
21. Klasa RJ, Hoskins PJ, O'Reilly SE, Fairey R, Voss N, Gascoyne R, Connors JM: Treatment of advanced stage low grade lymphoma with BP-VACOP and extensive lymph node irradiation (RT). 5th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 9-12, 1993, p 96 (abstr)
22. McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Romaguera J, Rodriguez MA, Lee MS, Pate O, Sarris A, Younes A, Ut MD: Intensive conventional dose chemotherapy for stage IV low grade lymphoma: High remission rates, and reversion to negative of peripheral blood bcl-2 rearrangement. 5th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 9-12, 1993, p 96 (abstr)
23. Rohatiner AZS, Freedman A, Nadler L, Lin J, Lister TA: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. 5th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 9-12, 1993, p 40 (abstr)
24. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517, 1982
25. Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha Interferon. Blood 73:651, 1989
26. Grossbard ML, Nadler LM: Immunotoxin therapy of malignancy, in DeVita VT, Rosenberg SA, Hellman S (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1992, p 111
27. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD, Wahl RL: Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459, 1993
28. Press OW, Eary JF, Badger CC, Martin PJ, Applebaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA: Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7:1027, 1989
29. DeNardo SJ, DeNardo GL, O'Grady LF, Hu E, Sytsma VM, Mills SL, Levy NB, Macey DJ, Miller CH, Epstein AL: Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl 3:96, 1988
30. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenburg H, Lee RE, Stein R, Siegel JA, Izon DO: Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9:548, 1991
31. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
32. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan FJ, Rodriguez MA, Plunkett WK, Keating MJ: Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 10:790, 1992
33. Hochster HS, Kim KM, Green MD, Mann RB, Neiman RS, Oken MM, Cassileth PA, Stott P, Ritch P, O'Connell MJ: Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10:28, 1992
34. Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, Piro LD: 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 10:371, 1992
35. Cleary ML, Sklar J: Nucleotide sequence of a t(14; 18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82:7439, 1985
36. Tsujimoto Y, Cossman J, Jaffe E, Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440, 1985
37. Zelenetz A, Chu G, Galili N, Bangs CD, Horning SJ, Donlon TA, Cleary ML, Levy R: Enhanced detection of the t(14; 18) translocation in malignant lymphoma using pulsed-field gel electrophoresis. Blood 78:1552, 1991
38. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ: Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602, 1990
39. Chen LZ, Nourse J, Cleary ML: The bcl-2 candidate protooncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14; 18) translocation. Mol Cell Biol 9:701, 1989
40. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334, 1990
41. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC: Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361:365, 1993
42. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ: bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79, 1989
43. Bahler D, Levy R: Clonal evolution of a follicular lymphoma: Evidence for antigen selection. Proc Natl Acad Sci USA 89: 6770, 1992
44. Zelenetz AD, Chen TT, Levy R: Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. J Exp Med 176:1137, 1992
45. Miyashita T, Reed JC: Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407, 1992
46. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ: bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67:879, 1991
47. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609, 1993
48. Pezzella F, Jones M, Ralfkiaer E, Ersboll J, Gatter KC, Mason DY: Evaluation of bcl-2 protein expression and 14; 18 translocation as prognostic markers in follicular lymphoma. Br J Cancer 65:87, 1992
49. Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, Barber M, Saporito L, Woo SD, Coral F, Spector N, Rabinowe SN, Grossbard ML, Ritz J, Nadler LM: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449, 1993
50. Price CG, Meerabux J, Murtagh S, Cotter FE, Rohatiner AZ, Young BD, Lister TA: The significance of circulating cells carrying t(14; 18) in long remission from follicular lymphoma. J Clin Oncol 9:1527, 1991